Westlake Epoxy Unveils EpoVIVE™ Portfolio at ECS 2025: A New Era of Sustainable Solutions
24.3.2025 21:52:00 CET | Business Wire | Press release
Westlake Corporation (NYSE: WLK) announced today that Westlake Epoxy plans to launch several new products at the European Coatings Show (ECS) 2025, March 25 to 27, 2025, in Germany. Westlake Epoxy will be showcasing at booth # 5-349 its latest innovations designed to enhance robustness, safety, and performance.
At Westlake, we challenge ourselves to do more, to go further in our quest for improved sustainability. As such we strive to develop new technologies that help support customer sustainability initiatives. We are proud to present at ECS our newly introduced EpoVIVE™ portfolio of products that provide sustainability advantages as compared to traditional Westlake formulas in one or more of the following categories:
- Lower Carbon Footprint: Utilize ISCC PLUS mass-balanced bio circular or circular raw materials to reduce carbon emissions.
- Energy Efficiency: Combine renewable energy with energy-efficient practices to reduce the carbon footprint.
- Safer Materials: Use of safer materials that are free from SVHC (substances of very high concern) and CMR (carcinogenic, mutagenic and reprotoxic), improving safe handling.
- Emission Reductions: Achieve lower VOC (volatile organic compounds) waterborne epoxy resin dispersions, contributing to the reduction of VOC emissions during customer applications.
- More Circular Solutions: Support improved circularity with innovative formulations and recycling processes that allow for enhanced ability to reuse, recycle, or repurpose products in the EpoVIVE™ portfolio.
Designed to meet the increasing demand for low-emission, and SVHC-free alternatives that use bio-circular or circular materials, these cutting-edge products offer enhanced durability, corrosion protection, and ease of use while improving our environmental footprint through operational innovations and product offerings with reduced environmental impacts.
The EpoVIVE™ range introduces NEW EPIKOTE™ Resins 901 and 902, providing CMR-free alternatives to conventional C12-C14 diluted resins for high-performance flooring. The portfolio also features the AQUAREOUS™ epoxy systems enabling lower volatile organic compound (VOC), solvent-free coatings for concrete and metal, while SVHC-free AZURES™ products deliver CMR free labelled, high-performance solutions for coatings, civil engineering, and adhesives.
In addition to the EpoVIVE™ portfolio, Westlake Epoxy will introduce the ENABLING Curing Agent EPIKURE™ 6874-WZ-50, which simplifies waterborne formulations and enhances corrosion protection for smooth steel.
"Our commitment to improved sustainability drives us to continuously innovate and deliver solutions that help our customers meet their environmental and performance goals. The launch of the EpoVIVE™ portfolio and related product developments reflect Westlake Epoxy's dedication to reducing the environmental impact of our products while maintaining our high standards of quality and performance," said Karl-Martin Schellerer, Westlake Senior Vice President — Performance and Essential Materials, Europe and Asia.
To learn more about EpoVIVE™ products and Westlake Epoxy’s new innovations for the coatings industry, we invite you to participate in the presentations “New Low labelled Resin Blends for Epoxy Flooring Applications” presented by Patrick Deudon, on Tuesday, March 25th at 14:30 – 14:50, booth # 3-742, Hall 3, and “Novel Waterborne Epoxy Systems: Boosting your Coating Performance”, presented by Dominique Vandenberghe, on Wednesday, March 26th at 13:50 – 14:10, booth # 5-243, Hall 5.
Westlake Epoxy aspires to continuously improve its Environmental, Sustainable and Governance journey. Westlake Epoxy is committed to reducing its carbon footprint through purposefully sourcing more sustainable raw materials, and refining and improving manufacturing processes. Together, we are enhancing your life every day!
About Westlake
Westlake Corporation (NYSE: WLK) is a global manufacturer and supplier of materials and innovative products that enhance life every day. Headquartered in Houston, with operations in Asia, Europe, and North America, we provide the building blocks for vital solutions — from housing and construction, to packaging and healthcare, to automotive and consumer. For more information, visit the company's web site at www.westlake.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250324929717/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom